HomeSponsoredManaging and treating patients with VTEPreventing VTE recurrence
Managing and treating patients with VTE
Preventing VTE recurrence
This is promotional content, intended for UK healthcare professionals only. This webpage has been developed and funded by the Bristol-Myers Squibb / Pfizer Alliance.
Click here to view ELIQUIS® (apixaban) prescribing and adverse event reporting information.
This section addresses the long-term management of patients with VTE, which may involve:
Understanding the risk of VTE recurrence
Determining which patients may benefit from extended anticoagulation
Involving patients in the decision-making process
Evidence for the long-term prevention of VTE recurrence by anticoagulants
Adverse events should be reported. Reporting forms and information can be found via United Kingdom – The yellow card scheme at www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Bristol-Myers Squibb via email@example.com or 0800 731 1736 (United Kingdom).